Search results - 6 results
Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factorsBackgroundMethodsResultsConclusionDataSheet_1.docx
https://sciensano.be/en/10.3389/fimmu.2022.1062136 Version: Published Full text access: Public Access Full text language: English Category: Peer-reviewed scientific articles FOS Classification: 3.02 Clinical medicine ...
Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naïve nursing home residents and healthy adults.
Classification: 3.02 Clinical medicine ...
Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with CancerPurpose:Experimental Design:Results:Conclusions:
Christof; Lion, Eva; Peeters, Marc; van Dam, Peter A. Source: Clinical Cancer Research, Volume 29, Issue 3 (2022) Health Topics: Coronavirus Coronavirus Coronavirus Manuscript versions: DOI: ...
The prior infection with SARS-CoV-2 study (PICOV) in nursing home residents and staff- study protocol description and presentation of preliminary findings on symptoms.
infections (ARI). However, little is known, about the impact of a previous or current infection on the other in terms of susceptibility, immune response, and clinical course. The aim of the “Prior Infection ...
Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma.
Maes; Alexander Schauwvlieghe; Laurens Liesenborghs; Ann Belmans; Peter Verhamme; Geert Meyfroidt; DAWn-plasma investigators Source: Eur Respir J (2021) Abstract: BACKGROUND: Several randomised clinical ...
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the DAWn-Plasma trial.
n-Plasma is a multicentre nation-wide, randomized, open-label, phase II proof-of-concept clinical trial, evaluating the clinical efficacy and safety of the addition of convalescent plasma to the standard of ...